Conversations Around Tiered Screening Webinar Series Part 2: History of Second-tier Testing in Newborn Screening

The initial webinar provided a brief history of second-tier testing as it has been added throughout the years in newborn screening programs. Speakers provided an overview of the history of second-tier screening methods for Congenital Hypothyroidism (CH), Galactosemia, various Hemoglobinopathies, Cystic Fibrosis (CF), Tyrosinemia type I, Congenital Adrenal Hyperplasia (CAH), Homocystinuria (HCY), certain Lysosomal Disorders (LSDs), and Spinal Muscular Atrophy (SMA).

Speakers:

• Anne M. Comeau, PhD, Deputy Director, New England Newborn Screening Program, Professor, Department of Pediatrics, University of Massachusetts Medical School
• Patrick V. Hopkins, Newborn Screening Project Specialist, Missouri State Public Health Laboratory
• Patricia R. Hunt, Newborn Metabolic Screening Group Manager, Texas Department of State Health Services

This resource is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) under grant # U22MC24078. This information or content and conclusions are those of the authors and should not be construed as the official position or policy of, nor should any endorsements be inferred by HRSA, HHS or the US Government.